Washington Roundup
OIG: Who Knows Whether REMS Improve Drug Safety?
Are risk evaluation and mitigation strategies (REMS) actually making any difference when it comes to drug safety? Enquiring minds at the Health and Human Services' Office of Inspector General (OIG) want to know. The trouble is the FDA doesn't have the data to answer the question.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter